Alessandra Pavesio is the Chief Science Officer at Bioventus, where she is responsible for leading R&D, Clinical and Regulatory Affairs, and providing strategic and operational leadership for the further growth of Bioventus products from early-stage development to commercial launch.
During Pavesio’s >20-year career, she has developed – from concept to bedside – more than 30 Class-III innovative medical devices, drugs and biologics, designed for treatment of osteoarthritis, and for regeneration of soft and hard tissues. A recognized opinion leader in cell based therapies, Pavesio revolutionized cartilage regeneration by conceiving and developing the first matrix assisted autologous chondrocyte implantation technology to reach the market. She has also served as chairperson of international regenerative medicine technology platforms and government advisory councils on innovation.
Prior to joining Bioventus, Pavesio held executive positions in Boston University, Anika Therapeutics and Fidia.
An accomplished innovator with 15 granted patented inventions on hyaluronon based technologies, Pavesio is the co-author of numerous peer reviewed publications.